Patents by Inventor Kun Guo

Kun Guo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFalpha) signaling pathway
    Publication number: 20070015699
    Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.
    Type: Application
    Filed: December 5, 2005
    Publication date: January 18, 2007
    Inventors: George Searfoss, Marco Pagnoni, Yuri Ivashchenko, Kun Guo, Kenneth Clark
  • Lock mechanism for digital disc player
    Publication number: 20060053430
    Abstract: A lock mechanism for a digital video player includes an elastic component, a switch, a main body, and a lid pivotally connected to the main body. The switch forms a switch button, a catch and a post for supporting the elastic component. The main body includes a cover and a housing. The cover defines a through hole thereon. The housing mounts at least one support for slideably supporting the switch, a stop plate connecting with the elastic component, and a second notch for accommodating the switch button. The lid mounts a hook on the bottom surface thereof corresponding to the through hole and being capable of hooking the catch when the lid is locked.
    Type: Application
    Filed: February 25, 2005
    Publication date: March 9, 2006
    Applicant: HON HAI Precision Industry CO., LTD.
    Inventors: Xiang-Hui Zhang, Shi-Kun Guo, Wen-Jie Bao
  • Variants of traf2 which act as an inhibitor of tnf-alpha (tnf?) signaling pathway
    Patent number: 6998475
    Abstract: The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF ? signaling path-way. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as “TRAF2 truncated-deleted” or “TRAF2TD”. Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF ? signaling pathway and in TRAF2TD, this ability is greatly enhanced, greatly reducing the response to TNF ? binding.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: February 14, 2006
    Assignee: Centelion SAS
    Inventors: George H. Searfoss, III, Marco F. Pagnoni, Yuri D. Ivashchenko, Kun Guo, Kenneth L. Clark
  • Akt nucleic acids, polypeptides, and uses thereof
    Publication number: 20050142603
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: February 23, 2005
    Publication date: June 30, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Marco Pagnoni, Kenneth Clark, Yuri Ivashchenko
  • AKT nucleic acids, polypeptides, and uses thereof
    Patent number: 6881555
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: April 19, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko
  • Establishment of an end to end virtual connection
    Publication number: 20030118033
    Abstract: A method for establishing an end-to-end virtual circuit is provided. The method includes establishing a permanent virtual circuit between customer premises equipment and a digital subscriber line access multiplexer. The method further includes embedding information for a permanent virtual connection between a switch and a remote node in a packet transmitted over a static connection in a network. Finally, the method includes establishing a permanent virtual circuit between the switch and the remote node based on the embedded information.
    Type: Application
    Filed: December 22, 2001
    Publication date: June 26, 2003
    Inventors: Celine Yonghong Wang, Kun Guo
  • AKT nucleic acids, polypeptides, and uses thereof
    Publication number: 20030100049
    Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
    Type: Application
    Filed: March 14, 2000
    Publication date: May 29, 2003
    Inventors: Kun Guo, Marco F. Pagnoni, Kenneth L. Clark, Yuri D. Ivashchenko